Trials / Completed
CompletedNCT03259581
Safety of Transarterial Chemoembolization (TACE) in the Setting of an Elevated Bilirubin
Safety of Transarterial Chemoembolization in Patients With Elevated Bilirubin
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- University of Minnesota · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate the safety of selective transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) in the setting of an elevated total bilirubin, but relatively normal direct bilirubin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | Transarterial chemoembolization | Delivery of lipiodol, chemotherapy (Deoxyrubicin), and particles (embosphere particles) to the arteries feeding hepatocellular carcinoma. While both chemotherapy and particles are delivered this is a single procedure in which the chemotherapy is delivered followed immediately by particles. |
Timeline
- Start date
- 2018-01-02
- Primary completion
- 2021-12-31
- Completion
- 2022-02-01
- First posted
- 2017-08-23
- Last updated
- 2022-03-21
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03259581. Inclusion in this directory is not an endorsement.